secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orgenesis Inc. (—)
CIK:        0001460602
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001493152-23-036355
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orgenesis subsidiary Koligo enters $25M convertible loan with Sai Traders; initial $1.5M at 10% interest
--------------------------------------------------------------------------------

- Koligo Therapeutics (Orgenesis sub) borrows up to $25M; initial $1.5M funded at closing.
- Interest 10% p.a.; maturity Dec 1, 2027; prepayable without penalty.
- Lender may convert into Orgenesis common at $2.50/share (initial) or $3.50/share (subsequent).
- Alternative conversion into Koligo equity at 75% of Qualified Financing price or 25% premium to 5-day VWAP if listed.
- Funds used for working capital and ongoing operations; shares unregistered, issued under Section 4(a)(2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1460602/000149315223036355/0001493152-23-036355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1460602/000149315223036355/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-036355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer